Clinical trial · Observational
MR Radiomic Features in Prostate Cancer
NCT04219059CI-TRIAL-00063485completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
A combination of correct interpretation of imaging and biopsy has given promising results in terms of detecting clinically significant cancer at radical prostatectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of surrogate bioimaging markers of histological characteristics in MR images
- timeFrame
- 0-2 years
- description
- Segment tumor volumes on the ADC map and extract different imaging features
Secondary outcomes (2)
- measure
- Radiomic features from MRI
- timeFrame
- 0-2 years
- description
- Evaluate if radiomic features on primitive prostate lesions can describe lymph node involvement.
- measure
- Extract radiomic features
- timeFrame
- 0-2 years
- description
- Evaluate if radiomic features fro MRIon primitive prostate lesions can describe disease extension.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years of age * In house MRI with contrast medium * PCa (prostate cancer) biopsy proven diagnosis * In house radical prostatectomy Exclusion Criteria: * \< 18 years of age * MRI without contrast medium * Radical prostatectomy executed not in Institution
References
Publications (0)
Data not yet available
No reference posted for this study.